Protara TherapeuticsTARA
About: Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Employees: 33
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
363% more call options, than puts
Call options by funds: $2.21M | Put options by funds: $478K
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
2% less funds holding
Funds holding: 60 [Q4 2024] → 59 (-1) [Q1 2025]
8.24% less ownership
Funds ownership: 86.45% [Q4 2024] → 78.22% (-8.24%) [Q1 2025]
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
21% less capital invested
Capital invested by funds: $157M [Q4 2024] → $124M (-$32.8M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Jones Trading Soumit Roy | 560%upside $21 | Buy Initiated | 22 May 2025 |
Financial journalist opinion









